How Are European Countries Assessing Digital Health Technologies (DHTS)? A Comparison of DHT Health Technology Assessments (HTAS) Across France, Germany and the UK


Arca` E1, Heldt D2
1OPEN Health Evidence & Access, Rotterdam, ZH, Netherlands, 2OPEN Health, Berlin, BE, Germany

Presentation Documents

OBJECTIVES: To systematically identify and review HTAs of DHTs across France, Germany, and the UK.

METHODS: A systematic review of grey literature was conducted whereby national-level HTA websites from HAS, BfArM, and NICE were searched. The authors restricted inclusion to stand-alone DHTs falling under Tier C of the NICE assessment framework,1 and/or under BfArM’s definition of digital health apps.2 To improve consistency and minimize variability across assessments, we extracted and analyzed only HTAs of the same DHTs submitted and evaluated for the same indications across multiple agencies.

RESULTS: In total, 54 assessments were identified across the three agencies. Four were identified for France, 30 for Germany, and 20 for the UK. Consistently across the three countries, the disease area with the most submissions was mental/behavioral health, followed by cardiology, diabetes, and oncology. Only two products were assessed by multiple agencies, namely Deprexis and Velibra. Deprexis was first assessed in the UK (January 2018),3 followed by Germany (February 2021),4 and France (December 2021).5 Velibra was assessed in the UK (July 2019)6,7,8 and in Germany (October 2020).9 Despite recognition of the high unmet need, the results of the Deprexis and Velibra assessments varied greatly across France, Germany, and the UK. While Deprexis was not recommended in France, both apps were recommended for reimbursement in Germany. In the UK, Deprexis was recommended for inclusion in the Improving Access to Psychological Therapies program but Velibra was not. The reasons for the divergence were related to the positioning of the products, the submitted evidence, and its quality, and chosen comparator treatments.

CONCLUSIONS: This review provides an overview of the status of HTA frameworks and evidence requirements for DHTs across three major European markets. Although every healthcare system is unique, a common European approach to HTA for DHTs could facilitate innovation and access.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Acceptance Code



Health Technology Assessment, Medical Technologies

Topic Subcategory

Decision & Deliberative Processes, Systems & Structure, Value Frameworks & Dossier Format


sdc-cardiovascular-disorders-including-mi-stroke-circulatory, sdc-diabetes-endocrine-metabolic-disorders-including-obesity, sdc-oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now